Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanoma
Dirk Tomsitz(LMU Klinikum), Lucie Heinzerling(Friedrich-Alexander-Universität Erlangen-Nürnberg), Edgar Dippel(Klinikum Ludwigshafen), Rudolf Herbst(Helios Klinikum Erfurt), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Michael Weichenthal(Christian-Albrechts-Universität zu Kiel), Claudia Pföhler(Saarland University), Dirk Schadendorf(National Center for Tumor Diseases), Friedegund Meier(National Center for Tumor Diseases), Ricarda Rauschenberg(National Center for Tumor Diseases), Elisabeth Livingstone(German Cancer Research Center), Peter J. Mohr(Roche (Switzerland)), Carola Berking(Universitätsklinikum Erlangen), Selma Ugurel(Klinikum Bielefeld), Frank Meiß(University of Freiburg), Fiona Brunnert(Elbe Kliniken Stade-Buxtehude), Lisa Zimmer(The University of Sydney), Jessica C. Hassel(German Cancer Research Center), Carmen Loquai(Johannes Gutenberg University Mainz), Alexander Kreuter(HELIOS St. Elisabeth Klinik Oberhausen), Ulrike Leiter(University of Tübingen), Martin Kaatz(SRH Wald-Klinikum Gera), Imke von Wasielewski(Medizinische Hochschule Hannover), Michael Sachse(Klinikum Bremerhaven-Reinkenheide), Patrick Terheyden(University Hospital Schleswig-Holstein), Jens Ulrich, Bastian Schilling(Goethe University Frankfurt)
Cited by 2
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k